Tags : Karyopharm

Karyopharm’s Xpovio (selinexor) Receives FDA’s Accelerated Approval for Relapsed/Refractory Multiple

Shots: The accelerated approval is based P-IIb STORM study results assessing Xpovio (80mg) + dexamethasone (20mg) in 122 patients with RRMM, prior treated with 4 therapies with the refractory disease to at least two proteasome inhibitors, immunomodulatory agent and anti-CD38 mAb The P-II STORM resulted in 25.3% overall response rate (ORR) in the subgroup of […]Read More